Alnylam Pharmaceuticals (ALNY) Competitors

Alnylam Pharmaceuticals logo
$149.40 -7.10 (-4.54%)
Closing price 04:00 PM Eastern
Extended Trading
$149.38 -0.03 (-0.02%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALNY vs. ARGX, NTRA, RVMD, BIIB, and GMAB

Should you buy Alnylam Pharmaceuticals stock or one of its competitors? Alnylam Pharmaceuticals's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alnylam Pharmaceuticals compare to argenex?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to argenex's net margin of 31.66%. Alnylam Pharmaceuticals' return on equity of 155.33% beat argenex's return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals52.85% 155.33% 44.81%
argenex 31.66%47.70%40.12%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals presently has a consensus target price of $292.57, suggesting a potential upside of 86.94%. argenex has a consensus target price of $1,163.18, suggesting a potential upside of 22.76%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than argenex. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 11 mentions for argenex. argenex's average media sentiment score of 0.42 beat Alnylam Pharmaceuticals' score of 0.13 indicating that argenex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
argenex
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

argenex has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$3.71B5.64$313.75M$19.268.13
argenex$4.25B14.03$1.29B$28.6633.06

Alnylam Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, argenex has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Summary

argenex beats Alnylam Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Natera?

Natera (NASDAQ:NTRA) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

99.9% of Natera shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than Natera. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 13 mentions for Natera. Natera's average media sentiment score of 0.57 beat Alnylam Pharmaceuticals' score of 0.13 indicating that Natera is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natera
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alnylam Pharmaceuticals has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$2.31B18.08-$208.16M-$1.14N/A
Alnylam Pharmaceuticals$3.71B5.64$313.75M$19.268.13

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Natera's net margin of -5.66%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Natera-5.66% -8.61% -5.93%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

Natera has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Natera presently has a consensus target price of $394.31, indicating a potential upside of 37.17%. Alnylam Pharmaceuticals has a consensus target price of $292.57, indicating a potential upside of 86.94%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Natera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Natera and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Revolution Medicines?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Revolution Medicines' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals52.85% 155.33% 44.81%
Revolution Medicines N/A -84.51%-51.97%

Alnylam Pharmaceuticals currently has a consensus price target of $292.57, suggesting a potential upside of 86.94%. Revolution Medicines has a consensus price target of $262.75, suggesting a potential upside of 61.50%. Given Alnylam Pharmaceuticals' higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92

Alnylam Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

In the previous week, Revolution Medicines had 2 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 18 mentions for Revolution Medicines and 16 mentions for Alnylam Pharmaceuticals. Revolution Medicines' average media sentiment score of 0.63 beat Alnylam Pharmaceuticals' score of 0.13 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Revolution Medicines
4 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$3.71B5.64$313.75M$19.268.13
Revolution Medicines$11.58M3,038.71-$1.13B-$9.11N/A

Summary

Revolution Medicines beats Alnylam Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Biogen?

Biogen (NASDAQ:BIIB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Biogen presently has a consensus price target of $254.41, indicating a potential upside of 1.44%. Alnylam Pharmaceuticals has a consensus price target of $292.57, indicating a potential upside of 86.94%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Biogen's net margin of 3.37%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Biogen had 20 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 36 mentions for Biogen and 16 mentions for Alnylam Pharmaceuticals. Biogen's average media sentiment score of 1.14 beat Alnylam Pharmaceuticals' score of 0.13 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
18 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.75$1.29B$2.34107.18
Alnylam Pharmaceuticals$3.71B5.64$313.75M$19.268.13

Summary

Alnylam Pharmaceuticals beats Biogen on 9 of the 16 factors compared between the two stocks.

How does Alnylam Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.72B8.72$963M$1.1744.41
Alnylam Pharmaceuticals$3.71B5.64$313.75M$19.268.13

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Genmab A/S's net margin of 16.97%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S16.97% 13.67% 6.42%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

In the previous week, Alnylam Pharmaceuticals had 9 more articles in the media than Genmab A/S. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 7 mentions for Genmab A/S. Alnylam Pharmaceuticals' average media sentiment score of 0.13 beat Genmab A/S's score of -0.18 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Genmab A/S presently has a consensus price target of $53.50, suggesting a potential upside of 2.96%. Alnylam Pharmaceuticals has a consensus price target of $292.57, suggesting a potential upside of 86.94%. Given Alnylam Pharmaceuticals' higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Genmab A/S has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Genmab A/S on 9 of the 16 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALNY vs. The Competition

MetricAlnylam PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$20.01B$3.97B$7.60B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio7.7624.6233.5830.13
Price / Sales5.3915.528.275.60
Price / Cash57.1322.9521.0121.90
Price / Book5.554.164.443.72
Net Income$313.75M-$24.10M$3.50B$393.88M
7 Day Performance-6.54%-8.44%-6.53%-6.07%
1 Month Performance-35.56%-6.54%-4.93%-7.38%
1 Year Performance-67.68%-6.71%-1.73%-7.48%

Alnylam Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALNY
Alnylam Pharmaceuticals
4.788 of 5 stars
$149.40
-4.5%
$292.57
+95.8%
-66.0%$20.01B$3.71B7.762,770
ARGX
argenex
4.5891 of 5 stars
$969.17
-1.2%
$1,155.24
+19.2%
+1.9%$60.96B$4.25B33.821,863
NTRA
Natera
3.216 of 5 stars
$317.84
-1.6%
$394.31
+24.1%
+39.5%$46.07B$2.31BN/A6,140
RVMD
Revolution Medicines
3.3468 of 5 stars
$173.46
-1.6%
$262.75
+51.5%
+135.3%$37.39B$11.58MN/A883
BIIB
Biogen
2.9767 of 5 stars
$252.70
+0.9%
$254.41
+0.7%
+52.3%$37.36B$10.30B108.027,500

Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners